Gene and Cell Therapies Targeting CNS Disorders Market Size, Share & Trends Analysis Report By Products (Gene Therapy and Cell Therapy), By Indications, Region And Segment Forecasts, 2025-2034

Gene and Cell Therapies Targeting CNS Disorders Market is expected to grow at a 30.5% CAGR during the forecast period of 2025-2034.

Key Industry Insights & Findings from the Report:

• The growing incidence of central nervous system (CNS) illnesses and the increasing need for efficient treatments are anticipated to propel the market for gene & cell therapies targeting CNS disorders.
• Increasing regulatory approvals for gene therapy products are expected to drive the gene and cell therapies targeting CNS disorders market.
• North America dominated the market and accounted for a global revenue share in 2023.
• The market is expected to be greatly impacted by difficult issues such as the intricacy of delivery, immunological reactions, safety apprehensions, regulatory hurdles, and ethical considerations. 

Cell and gene therapy-based therapies have the potential to be an effective and disease-modifying treatment for diseases that would otherwise be incurable with traditional medicines. Due to the rising demand for cell-based immunotherapies and gene therapy products to treat conditions such as prostate and blood cancers. Another factor driving market expansion is the increasing use of cell therapy products in hospitalized patients to treat burns, venous leg ulcers, diabetic foot ulcers, traumas, and pressure ulcers. Also, due to excellent safety and efficacy profiles for treating a wide range of disorders, specific cell and gene therapy treatments are getting regulatory approvals faster than other medicines. As the approval process becomes more simplified, companies are launching these items on the market more quickly.

Additionally, rising R&D efforts, government initiatives to utilize sustainable components in manufacturing, and investments by major players are likely to generate lucrative revenue opportunities for players in the global Gene and Cell Therapies Targeting CNS Disorders Targeting CNS Disorders market over the forecast period. During the projection period, the recurrence of the current pandemic is likely to have a positive impact on the worldwide Gene and Cell Therapies Targeting CNS Disorders market. Due to the increased intervention of life-threatening diseases such as heart disease, AIDS, cystic fibrosis, and age-related problems, the industry is likely to expand its borders. The high cost of gene treatments, on the other hand, is expected to hinder market expansion to some extent throughout the forecast period. 

Competitive Landscape

Some of The Key Players in the Gene and Cell Therapies Targeting CNS Disorders Market:

• Novartis
• BrainStorm Cell Therapeutics
• Helixmith
• Corestem
• Q therapeutics
• Helixmith
• Rapa Therapeutics
• Neuroplast
• StemCyte
• Ferrer International
• Neuralstem
• Ferrer Internacional
• Stemedica Cell Technologies
• Libella Gene Therapeutics
• Sangamo Therapeutics
• Hoffmann-La Roche
• Longeveron
• Sio Gene Therapies
• Prevail Therapeutics (Eli Lilly and Company)
• NeuroGeneration
• Brain Neurotherapy Bio (AskBio)
• UniQure Biopharma
• Neurogene Inc.
• Passage Bio
• AXOVANT SCIENCES GMBH
• MeiraGTx Limited
• Asklepios BioPharmaceutical (AskBio)
• Biogen
• Sarepta Therapeutics
• REGENXBIO Inc.
• Lysogene
• Voyager Therapeutics
• PTC Therapeutics
• Other Prominent Players

Market Segmentation:

The Gene and Cell Therapies Targeting CNS Disorders market is segmented based on product and Indication. Based on the product, the market is segmented as gene therapy and cell therapy. By Indication, the market is segmented into amyotrophic Lateral Sclerosis, Multiple sclerosis, Spinal Cord Injure, Alzheimer, Parkinson Disease, Huntington, and Other Indications. Based on Indications, the Huntington segment is accounted as a major contributor in the Gene and Cell Therapies Targeting CNS Disorders market. The Huntington category is expected to hold a major share in the global Gene and Cell Therapies Targeting CNS Disorders Targeting CNS Disorders market in 2021. As a result of the approval of an increasing number of gene therapies for cancer therapy and the segment's growth is being fueled by greater emphasis on research to develop effective cancer treatments, as well as rising cancer research investments.

The market is expected to develop in the coming years due to the availability of numerous gene therapy products that can be used to treat cancer and a huge patient population. Cell therapy segment witness growth at a rapid rate. The cell therapy segment is projected to grow at a rapid rate in the global Gene and Cell Therapies Targeting CNS Disorders Targeting CNS Disorders market. The cell therapy segment is growing due to the introduction of innovative and breakthrough products as well as the widespread use of CAR T-cell-based therapies. Cell therapy is the most rapidly developing technology in cancer treatment, with the potential to replace multiple present treatments., especially in countries such as the US, Germany, UK, China, and India.

The North America Gene and Cell Therapies Targeting CNS Disorders market hold a significant revenue share in the region.

The North America gene and cell therapy market is expected to show the highest market share in terms of revenue soon. In both regional and global markets, the United States is the major contributor. This is due to the introduction of novel cell and gene therapy products. Due to the elevated prevalence of chronic diseases in countries like China and Japan, APAC is expected to become a key market during the forecast period. Developers of cell and gene therapies are receiving support from both the public and private sectors. In terms of R&D activity and financing to develop and commercialize cell and gene therapy products, North America and Europe are at the forefront. The regulatory approval process, particularly in the United States, is evolving and becoming favourable for vendors for developing cell and gene therapy products.

Recent Developments:

• In May 2022, Novartis and Voyager Therapeutics have entered into a license option deal to develop advanced gene therapy vectors that specifically target neurological illnesses. Under the terms of the partnership, Novartis had the privilege to assess new capsids from Voyager's TRACER platform and had the choice to obtain licenses for exclusive usage in Novartis' research of AAV gene treatments targeting three specific objectives.

The Gene and Cell Therapies Targeting CNS Disorders Market Report Scope